Industries > Pharma > Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2018-2028

Back to Pharma Reports

Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2018-2028

Retinal Disorder Drugs, Allergic, Inflammatory & Infective Drugs, Glaucoma Drugs, Dry Eye Drugs

PUBLISHED: 19 July 2018

PAGES: 223

PRODUCT CODE: PHA0324

SUBMARKET: Therapeutic Drugs

SKU: PHA0324 Categories: Pharma, Therapeutic Drugs Tags: Ophthalmics, PHA0324, PHA0327, PHA0335, PHA0367

The global ophthalmic drugs market was valued at $23bn in 2017. The market was dominated by the Retinal Disorder drug submarket which held 39.1% of the global ophthalmic drugs market.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 223-page report you will receive 83 tables and 71 figures– all unavailable elsewhere.

The 223-page report provides clear detailed insight into the top ophthalmic drugs manufacturers. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope

• Global ophthalmic drugs market revenue forecasts from 2018-2028

• Global ophthalmic drugs market revenue orecasts from 2018-2028, by submarket:
• Retinal Disorder Drugs
• Allergic, Inflammatory & Infective Drugs
• Glaucoma Drugs
• Dry Eye Drugs
• Other Ophthalmic Drugs

• Revenue forecasts from 2018-2028 of the leading ophthalmic drugs:
• Alphagan
• Avastin
• Azopt
• Eylea
• Lucentis
• Lumigan & Ganfort
• Other Ophthalmic Drugs
• Restasis
• Vigamix
• Xalatan/Xalacom

• Our study discusses the selected leading companies that are the major players in the ophthalmic drugs industry:
• Acucela
• Akorn
• Alimera Sciences
• Allergan
• Amakem
• Bayer
• Chengdu Kanghong
• EyeGate Pharmaceuticals
• Gene Signal
• Icon Biosciences
• MacuCLEAR
• Neurotech
• Novartis
• Omeros
• Ophthotech
• Otsuka Pharmaceutical
• Pfizer
• pSivida Corp.
• Regeneron
• Roche
• Santen
• Senju
• Shire
• ThromboGenics
• Valeant

• Our report provides an overview, revenue forecast from 2018-2028 of the ophthalmic drugs segment, revenue forecast from 2018-2028 of the leading drugs, product pipeline and SWOT Analysis, for these companies:
• Akorn
• Alcon
• Allergan
• Bausch & Lomb
• Bayer
• Novartis
• Pfizer
• Regeneron
• Roche
• Santen
• Senju
• Valeant

• Our report provides these Qualitative Analysis:
• Drivers and Restraints of the Global Ophthalmic Drugs market
• SWOT Analysis of selected leading companies
• Porter’s Five Forces Analysis of the Global Ophthalmic Drugs Market

Visiongain’s study is intended for anyone requiring commercial analyses for the ophthalmic drugs market. You find data, trends and predictions.

Buy our report today Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2018-2028: Retinal Disorder Drugs, Allergic, Inflammatory & Infective Drugs, Glaucoma Drugs, Dry Eye Drugs.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

1. Report Overview

1.1 Global Ophthalmic Drugs Market Overview

1.2 Global Ophthalmic Drugs Market Segmentation

1.3 Why You Should Read This Report

1.4 How This Report Delivers

1.5 Key Questions Answered by This Analytical Report

1.6 Who is This Report For?

1.7 Methodology

1.8 Frequently Asked Questions (FAQ)

1.9 Associated Visiongain Reports

1.10 About Visiongain

2. Introduction to Ophthalmic Drugs

2.1 The Pharmaceutical Industry: Very Brief Overview

2.2 The Global Burden of Eye Disease

2.3 Ophthalmic Drugs: Market Segmentation

2.4 Glaucoma: the ‘Silent Thief of Sight’

2.4.1 A Classification of Glaucoma

2.4.2 Risk Factors for Glaucoma

2.4.3 Diagnosis of Glaucoma

2.4.4 Drug Treatment of Glaucoma

2.4.5 Laser Treatment and Surgery for Glaucoma

2.5 Age-Related Macular Degeneration (AMD)

2.5.1 Dry (Non-Exudative) AMD

2.5.2 Wet (Exudative) AMD

2.5.3 Risk Factors for AMD

2.5.4 Diagnosis of AMD

2.5.5 Treatment of AMD

2.6 Diabetic Retinopathy (DR)

2.6.1 Diagnosis of Diabetic Retinopathy

2.6.2 Treatment of Diabetic Retinopathy

2.7 Ocular Allergy and Allergic Conjunctivitis

2.7.1 Diagnosis of Ocular Allergy

2.7.2 Treatment of Ocular Allergy

2.8 Ocular Inflammatory Disease

2.8.1 Treatment of Ocular Inflammatory Disease

2.9 Eye Infections

2.9.1 Treatment of Eye Infections

2.10 Dry Eye Syndrome

2.10.1 Treatment of Dry Eye Syndrome

2.11 Phases of Clinical Trials

3. Ophthalmic Drugs: World Market 2018-2028

3.1 The World Ophthalmic Drugs Market in 2018

3.2 World Ophthalmic Drugs Market: Sales Forecast 2018-2028

3.3 Leading Ophthalmic Drugs

3.4 Leading Companies in the Ophthalmic Drugs Market

3.4.1 Top 25 Ophthalmic Drug Manufacturers

3.5 Ophthalmic Drugs Market Segments: Sales Forecasts 2018-2028

3.5.1 Retinal Disorders Drugs Market: Sales Forecast 2018-2028

3.5.2 Allergic, Inflammatory and Infective Drugs Market: Sales Forecast 2018-2028

3.5.3 Glaucoma Drugs Market: Sales Forecast 2018-2028

3.5.4 Dry Eye Drugs Market: Sales Forecast 2018-2028

3.5.5 Other Ophthalmic Drugs Market: Sales Forecast 2018-2028

3.6 How Will Market Shares Change to 2028?

3.7 World Ophthalmic Drugs Market: Drivers and Restraints 2018-2028

3.7.1 World Ophthalmic Drugs Market: Analysis of Drivers

3.7.2 World Ophthalmic Drugs Market: Analysis of Restraints

4. Leading US Ophthalmic Drug Manufacturers 2018-2028

4.1 Allergan Overview

4.1.1 Allergan: Ophthalmic Product Portfolio

4.1.2 Allergan: Late Stage Ophthalmic Product Pipeline

4.1.3 Allergan: Ophthalmic Revenue Forecast 2018-2028

4.1.4 Allergan: SWOT Analysis

4.2 Pfizer Overview

4.2.1 Pfizer: Ophthalmic Product Portfolio

4.2.2 Pfizer: Ophthalmic Product Pipeline

4.2.3 Pfizer: Revenue Forecast 2018-2028

4.2.4 Pfizer: SWOT Analysis

4.3 Regeneron Overview

4.3.1 Regeneron: Ophthalmic Product Portfolio

4.3.2 Regeneron: Ophthalmic Product Pipeline

4.3.3 Regeneron: Revenue Forecast 2018-2028

4.3.4 FDA Approves Zaltrap (aflibercept)

4.3.5 Eylea/Zaltrap and the Davis-Smyth Patent Agreements

4.3.6 Regeneron: SWOT Analysis

4.4 Akorn Overview

4.4.1 Akorn: Ophthalmic Product Portfolio

4.4.2 Akorn: Revenue Forecast 2018-2028

4.4.3 Akorn: SWOT Analysis

5. Leading European Ophthalmic Drug Manufacturers 2018-2028

5.1 Bayer Overview

5.1.1 Bayer: Ophthalmic Product Pipeline

5.1.2 Eylea: non-US Sales Forecast 2018-2028

5.1.3 Bayer: Revenue Forecast 2018-2028

5.2 Novartis (including Alcon) Overview

5.2.1 Novartis: Ophthalmic Product Portfolio

5.2.2 Novartis: Ophthalmic Product Pipeline

5.2.3 Novartis: Revenue Forecast 2018-2028

5.2.4 Novartis: SWOT Analysis

5.3 Roche Overview

5.3.1 Roche: Ophthalmic Product Portfolio

5.3.2 Roche: Ophthalmic Product Pipeline

5.3.3 Roche: Revenue Forecast 2018-2028

5.3.4 Roche: SWOT Analysis

6. Leading Asia-Pacific and Other Ophthalmic Drug Manufacturers 2018-2028

6.1 Santen Overview

6.1.1 Santen: Ophthalmic Product Portfolio

6.1.2 Santen: Ophthalmic Product Pipeline

6.1.3 Santen: Revenue Forecast 2018-2028

6.1.4 Santen: SWOT Analysis

6.2 Senju Overview

6.2.1 Senju: Ophthalmic Product Portfolio

6.2.2 Senju: Ophthalmic Product Pipeline

6.2.3 Senju: Revenue Forecast 2018-2028

6.2.4 Senju: SWOT Analysis

6.3 Valeant Overview

6.3.1 Valeant: Ophthalmic Product Portfolio

6.3.2 Valeant: Ophthalmic Product Pipeline

6.3.3 Valeant: Revenue Forecast 2018-2028

6.3.4 Valeant: SWOT Analysis

7. Emerging Ophthalmic Drug Manufacturers in 2017

7.1 Companies with Small Ophthalmic Portfolios and Promising Pipeline Candidates, 2017

7.2 Acucela

7.3 Aerie Pharmaceuticals

7.4 Aerpio Therapeutics: Developing AKB 9778

7.5 Alimera Sciences

7.5.1 Iluvien: Increasing Geographical Reach and Increasing Sales

7.5.2 NADPH Oxidase Inhibitors Offer Potential for Dry AMD

7.6 Amakem

7.7 Ampio Pharmaceuticals

7.8 Chengdu Kanghong Pharmaceutical

7.9 Eleven Biotherapeutics

7.10 EyeGate Pharmaceuticals

7.11 Gene Signal

7.11.1 Aganirsen: Preventing Corneal Graft Rejection

7.12 Icon Bioscience

7.13 MacuCLEAR

7.13.1 MC 1101: a Potential Therapy for Dry AMD

7.14 Neurotech

7.15 Omeros

7.16 OphthaliX (Can-Fite BioPharma)

7.17 Ophthotech

7.17.1 Fovista: Potential Game-Changer in AMD

7.17.2 Fovista: Significant Improvement on Lucentis in Phase II Trials

7.17.3 Zimura: Complement C5 Inhibitor

7.18 Otsuka Pharmaceutical

7.19 pSivida Corp.

7.20 RXi Pharmaceuticals: Will Bevasiranib Resume Development?

7.21 Shire

7.21.1 Lifitegrast (SHP606) for Dry Eye

7.21.2 Premiplex (SHP607): Preventing Retinopathy of Prematurity

7.22 ThromboGenics

7.22.1 Jetrea (ocriplasmin)

7.22.2 ThromboGgenics: Leading Diabetic Eye Disease Pipeline

8. Qualitative Analysis of the Ophthalmic Drugs Market 2018-2028

8.1 Porter’s Five Forces Analysis of the Ophthalmic Drugs Market

8.1.1 Rivalry Among Competitors [Medium]

8.1.2 Threat of New Entrants [Low]

8.1.3 Power of Suppliers [Low]

8.1.4 Power of Buyers [Medium]

8.1.5 Threat of Substitutes [Medium]

9. Conclusions

9.1 Ophthalmic Pharmaceuticals: A Growing Niche Market

9.2 The World Ophthalmic Drugs Market in 2017

9.2.1 Leading Ophthalmic Drugs Market Segments

9.2.2 Leading Ophthalmic Drugs

9.2.3 Leading Ophthalmic Drugs Companies

9.3 World Ophthalmic Drugs Market Forecast 2018-2028

9.4 The Future of the Ophthalmic Drugs Market?

9.4.1 Increasing Revenue Concentration among Specialist Companies

9.4.2 The Rise of Generics

9.4.3 Small Companies Can Have a Big Impact

9.4.4 What Will Succeed in the Ophthalmic Drugs Market?

Glossary

Associated Visiongain Reports

Visiongain Report Sales Order Form

Appendix A

About Visiongain

Appendix B

Visiongain report evaluation form

List of Tables

Table 2.1 ICD 10 Classification of Visual Impairment, 2015

Table 2.2 Drug Treatments for Glaucoma, 2017

Table 2.3 Drug Treatments for AMD, 2017

Table 2.4 Drug Treatments for Ocular Allergy, 2017

Table 2.5 Drug Treatments for Ocular Inflammatory Disease, 2017

Table 2.6 Selected Drug Treatments for Eye Infections, 2017

Table 2.7 Clinical Trial Phases

Table 3.1 World Ophthalmic Drugs Market: Revenue ($m) and Market Share (%) by Segment, 2017

Table 3.2 World Ophthalmic Drugs Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2018-2028

Table 3.3 Top 10 Ophthalmic Drugs: Revenue ($m), Market Share (%), Rank, Active Ingredient and Manufacturer, 2017

Table 3.4 Top 10 Ophthalmic Drug Manufacturers: Ophthalmic Drugs Revenue ($m), Market Share (%), 2017

Table 3.5 Top 25 Ophthalmic Drug Manufacturers: Ophthalmic Drugs Revenue ($m), Leading Pipeline Products, 2017

Table 3.6 World Ophthalmic Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%) by Segment, 2017-2028

Table 3.7 Retinal Disorders Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2017-2028

Table 3.8 Allergic, Inflammatory and Infective Drugs Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2017-2028

Table 3.9 Glaucoma Drugs Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2017-2028

Table 3.10 Dry Eye Drugs Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2017-2028

Table 3.11 Other Ophthalmic Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2017-2028

Table 3.12 Market Shares (%) of the Ophthalmic Drugs Market by Segment, 2017, 2023 and 2028

Table 4.1 Allergan: Overview, 2017

Table 4.2 Allergan: Ophthalmic Drug Products, Revenue ($m), Growth Rate (%), 2016 and 2017

Table 4.3 Allergan: Restasis Revenue ($m), AGR (%) and CAGR (%), 2017-2028

Table 4.4 Allergan: Lumigan and Ganfort Revenue ($m), AGR (%) and CAGR (%), 2017-2028

Table 4.5 Allergan: Alphagan/Alphagan P and Combigan Revenue ($m), AGR (%) and CAGR (%), 2017-2028

Table 4.6 Allergan: Ophthalmic Drugs Revenue ($m), AGR (%) and CAGR (%), 2017-2028

Table 4.7 Allergan: Ophthalmic Drugs Market Share (%), Revenue ($m), 2017-2028

Table 4.8 Allergan: Ophthalmic Drugs Market SWOT Analysis, 2018-2028

Table 4.9 Pfizer: Overview, 2017

Table 4.10 Pfizer: Xalatan/Xalacom Revenue ($m), AGR (%) and CAGR (%), 2017-2028

Table 4.11 Pfizer: Ophthalmic Drugs Revenue ($m), AGR (%) and CAGR (%), 2017-2028

Table 4.12 Pfizer: Ophthalmic Drugs Market Share (%), Revenue ($m), 2017-2028

Table 4.13 Pfizer: Ophthalmic Drugs Market SWOT Analysis, 2018-2028

Table 4.14 Regeneron: Overview, 2017

Table 4.15 Regeneron: Eylea Revenue ($m), AGR (%) and CAGR (%) 2017-2028

Table 4.16 Regeneron: Ophthalmic Drugs Revenue ($m), AGR (%) and CAGR (%), 2017-2028

Table 4.17 Regeneron: Ophthalmic Drugs Market Share (%), Revenue ($m), 2017-2028

Table 4.18 Regeneron: Ophthalmic Drugs Market SWOT Analysis, 2018-2028

Table 4.19 Akorn: Overview, 2017

Table 4.20 Akorn: Ophthalmic Drugs Revenue ($m), AGR (%) and CAGR (%), 2017-2028

Table 4.21 Akorn: Ophthalmic Drugs Market Share (%), Revenue ($m), 2017-2028

Table 4.22 Akorn: Ophthalmic Drugs Market SWOT Analysis, 2018-2028

Table 5.1 Bayer: Overview, 2017

Table 5.2 Bayer: Eylea Revenue ($m), AGR (%) and CAGR (%), 2017-2028

Table 5.3 Bayer: Ophthalmic Drugs Revenue ($m), AGR (%) and CAGR (%), 2017-2028

Table 5.4 Bayer: Ophthalmic Drugs Market Share (%), Revenue ($m), 2017-2028

Table 5.5 Novartis: Overview, 2017

Table 5.6 Novartis: Lucentis Revenue ($m), AGR (%) and CAGR (%), 2017-2028

Table 5.7 Novartis: Travatan/Travatan Z and DuoTrav Revenue ($m), AGR (%) and CAGR (%), 2017-2028

Table 5.8 Novartis: Vigamox Revenue ($m), AGR (%) and CAGR(%), 2017-2028

Table 5.9 Novartis: Azopt Revenue ($m), AGR (%) and CAGR(%), 2017-2028

Table 5.11 Novartis: Ophthalmic Drugs Revenue ($m), AGR (%) and CAGR (%), 2017-2028

Table 5.12 Novartis: Ophthalmic Drugs Market Share (%), Revenue ($m), 2017-2028

Table 5.13 Novartis: Ophthalmic Drugs Market SWOT Analysis, 2018-2028

Table 5.14 Roche: Overview, 2017

Table 5.15 Roche: Lucentis Revenue ($m), AGR (%) and CAGR(%), 2017-2028

Table 5.16 Roche: Avastin Ophthalmic Revenue ($m), AGR (%) and CAGR (%), 2017-2028

Table 5.17 Roche: Ophthalmic Drugs Revenue ($m), AGR (%) and CAGR (%), 2017-2028

Table 5.18 Roche: Ophthalmic Drugs Market Share (%), Revenue ($m), 2017-2028

Table 5.19 Roche: Ophthalmic Drugs Market SWOT Analysis, 2018-2028

Table 6.1 Santen: Overview, 2017

Table 6.2 Santen: Major Prescription Ophthalmic Drugs by Therapeutic Area, Launch Date, Region, 2017

Table 6.3 Santen: Eylea Revenue ($m), AGR (%) and CAGR(%), 2017-2028

Table 6.4 Santen: Hyalein Revenue ($m), AGR (%) and CAGR (%), 2017-2028

Table 6.5 Santen: Cosopt Revenue ($m), AGR (%) and CAGR (%), 2017-2028

Table 6.6 Santen: Tapros/Taflotan Revenue ($m), AGR (%) and CAGR (%), 2017-2028

Table 6.7 Santen: Diquas Revenue ($m), AGR (%) and CAGR (%), 2017-2028

Table 6.8 Santen: Cravit Revenue ($m), AGR (%) and CAGR (%), 2017-2028

Table 6.9 Santen: Alesion Revenue ($m), AGR (%) and CAGR (%), 2017-2028

Table 6.10 Santen: Ophthalmic Drugs Revenue ($m), AGR (%) and CAGR (%), 2017-2028

Table 6.11 Santen: Ophthalmic Drugs Market Share (%), Revenue ($m), 2017-2028

Table 6.12 Santen: Ophthalmic Drugs Market SWOT Analysis, 2018-2028

Table 6.13 Senju: Overview, 2017

Table 6.14 Senju: Major Prescription Ophthalmic Drugs by Therapeutic Area, Launch Year, 2017

Table 6.15 Senju: Ophthalmic Drugs Revenue ($m), AGR (%) and CAGR (%), 2017-2028

Table 6.16 Senju: Ophthalmic Drugs Market Share (%), Revenue ($m), 2017-2028

Table 6.17 Senju: Ophthalmic Drugs Market SWOT Analysis, 2018-2028

Table 6.18 Valeant: Overview, 2017

Table 6.19 Valeant: Lotemax Revenue ($m), AGR (%) and CAGR (%), 2017-2028

Table 6.20 Valeant: Ophthalmic Drugs Revenue ($m), AGR (%) and CAGR (%), 2017-2028

Table 6.21 Valeant: Ophthalmic Drugs Market Share (%), Revenue ($m), 2017-2028

Table 6.22 Valeant: Ophthalmic Drugs Market SWOT Analysis, 2018-2028

Table 7.1 Otsuka Pharmaceutical: Overview of Ophthalmic Drug Pipelines, Drug Type, Indication, Country

Table 9.1 Leading Ophthalmic Drugs Manufacturers: Revenues ($m), Market Share (%), 2018

List of Figures

Figure 1.1 Global Causes of Visual Impairment (% of cases), 2017

Figure 1.2 World 65+ Population Forecast: Size (millions), CAGR (%), by National Market, 2015 and 2026

Figure 1.3 Global Ophthalmic Drugs Market Segmentation Overview, 2017

Figure 2.1 Estimated Global Blindness and Visual Impairment (% of people), 2015

Figure 2.2 Estimated Global Prevalence of Visual Impairment (millions of people), 2015

Figure 2.3 Global Causes of Visual Impairment (% of cases), 2015

Figure 2.4 Global Causes of Blindness (% of cases), 2015

Figure 2.5 Classification of Glaucoma, 2017

Figure 3.1 World Ophthalmic Drugs Market: Revenues ($m) by Segment, 2017

Figure 3.2 World Ophthalmic Drugs Market: Market Share (%) by Segment, 2017

Figure 3.3 World Ophthalmic Drugs Market Forecast: Revenue ($m) and AGR (%), 2018-2028

Figure 3.4 Top 9 Ophthalmic Drugs: Revenues ($m), 2017

Figure 3.5 Top 9 Ophthalmic Drugs: Market Share (%), 2017

Figure 3.6 Top 10 Ophthalmic Drug Manufacturers: Ophthalmic Drugs Revenues ($m), 2017

Figure 3.7 Top 10 Ophthalmic Drug Manufacturers: Market Share (%), 2017

Figure 3.8 Retinal Disorders Drugs Market Forecast: Revenues ($m), 2017-2028

Figure 3.9 Allergic, Inflammatory and Infective Drugs Market Forecast: Revenue ($m), 2017-2028

Figure 3.10 Glaucoma Drugs Market Forecast: Revenues ($m), 2017-2028

Figure 3.11 Dry Eye Drugs Market Forecast: Revenues ($m), 2017-2028

Figure 3.12 Other Ophthalmic Drugs Market Forecast: Revenues ($m), 2017-2028

Figure 3.13 World Ophthalmic Drugs Market: Market Share (%) by Segment, 2017

Figure 3.14 World Ophthalmic Drugs Market Forecast: Market Shares (%) by Segment, 2023

Figure 3.15 World Ophthalmic Drugs Market Forecast: Market Shares (%) by Segment, 2028

Figure 3.16 World Ophthalmic Drugs Market: Drivers and Restraints, 2018-2028

Figure 4.1 Allergan: Restasis Revenue ($m) and AGR (%), 2017-2028

Figure 4.2 Allergan: Lumigan and Ganfort Revenue ($m) and AGR (%), 2017-2028

Figure 4.3 Allergan: Alphagan/Alphagan P and Combigan Revenue ($m) and AGR (%), 2017-2028

Figure 4.4 Allergan: Ophthalmic Drugs Revenue ($m) and AGR (%), 2017-2028

Figure 4.5 Allergan: Ophthalmic Drugs Revenue and Market Share (%), 2017-2028

Figure 4.6 Pfizer: Xalatan/Xalacom Revenue ($m), AGR (%), 2017-2028

Figure 4.7 Pfizer: Ophthalmic Drugs Revenue ($m) and AGR (%), 2017-2028

Figure 4.8 Pfizer: Ophthalmic Drugs Revenue and Market Share (%), 2017-2028

Figure 4.9 Regeneron: Eylea Revenue ($m) and AGR (%), 2017-2028

Figure 4.10 Regeneron: Ophthalmic Drugs Revenue ($m) and AGR (%), 2017-2028

Figure 4.11 Regeneron: Ophthalmic Drugs Revenue and Market Share (%), 2017-2028

Figure 4.12 Akorn: Ophthalmic Drugs Revenue ($m) and AGR (%), 2017-2028

Figure 4.13 Akorn: Ophthalmic Drugs Market Share (%), 2017-2028

Figure 5.1 Bayer: Eylea Revenue ($m) and AGR (%), 2017-2028

Figure 5.2 Bayer: Ophthalmic Drugs Revenue ($m) and AGR(%), 2017-2028

Figure 5.3 Bayer: Ophthalmic Drugs Revenue and Market Share (%), 2017-2028

Figure 5.4 Novartis: Lucentis Revenue ($m) and AGR(%), 2017-2028

Figure 5.5 Novartis: Travatan/Travatan Z and DuoTrav Revenue ($m) and AGR (%), 2017-2028

Figure 5.6 Novartis: Vigamox Revenue ($m) and AGR(%), 2017-2028

Figure 5.7 Novartis: Azopt Revenue ($m) and AGR (%), 2017-2028

Figure 5.8 Novartis: Ophthalmic Drugs Revenue ($m) and AGR (%), 2017-2028

Figure 5.9 Novartis: Ophthalmic Drugs Revenue and Market Share (%), 2017-2028

Figure 5.10 Roche: Lucentis Revenue ($m) and AGR (%), 2017-2028

Figure 5.11 Roche: Avastin Ophthalmic Revenue ($m) and AGR(%), 2017-2028

Figure 5.12 Roche: Ophthalmic Drugs Revenue ($m) and AGR (%), 2017-2028

Figure 5.13 Roche: Ophthalmic Drugs Revenue and Market Share (%), 2017-2028

Figure 6.1 Santen: Ophthalmic Drugs Revenue ($m) by Segment, FY 2017

Figure 6.2 Santen: Major Prescription Ophthalmic Drugs, Revenue Share (%), FY 2017

Figure 6.3 Santen: Eylea Revenue ($m) and AGR (%), 2017-2028

Figure 6.4 Santen: Hyalein Revenue ($m) and AGR (%), 2017-2028

Figure 6.5 Santen: Cosopt Revenue ($m) and AGR (%), 2017-2028

Figure 6.6 Santen: Tapros/Taflotan Revenue ($m) and AGR (%), 2017-2028

Figure 6.7 Santen: Diquas Revenue ($m) and AGR (%), 2017-2028

Figure 6.8 Santen: Cravit Revenue ($m) and AGR (%), 2017-2028

Figure 6.9 Santen: Alesion Revenue ($m) and AGR (%), 2017-2028

Figure 6.10 Santen: Ophthalmic Drugs Revenue ($m) and AGR (%), 2017-2028

Figure 6.11 Santen: Ophthalmic Drugs Market Share (%), 2017-2028

Figure 6.12 Senju: Ophthalmic Drugs Revenue ($m) and AGR (%), 2017-2028

Figure 6.13 Senju: Ophthalmic Drugs Market Share (%), 2017-2028

Figure 6.14 Valeant: Lotemax Revenue ($m) and AGR (%), 2017-2028

Figure 6.15 Valeant: Ophthalmic Drugs Revenue ($m) and AGR (%), 2017-2028

Figure 6.16 Valeant: Ophthalmic Drugs Market Share (%), 2017-2028

Figure 7.1 Gene Signal: Ophthalmic Drug Pipeline Progress

Figure 7.2 Ophthotech: Ophthalmic Drug Pipeline Progress

Figure 7.3 Otsuka Pharmaceutical: Ophthalmic Drug Pipeline Progress

Figure 7.4 Shire: Ophthalmic Drug Pipeline Progress

Figure 8.1 Porter’s Five Forces Analysis of the Ophthalmic Drugs Market, 2018-2028

Abbott Laboratories (Abbott)

Abbvie

Actavis

Acucela

Advanced Vision Research (acquired by Akorn)

Aerie Pharmaceuticals

Aerpio Therapeutics

Akorn Pharmaceuticals

Alcon (subsidiary of Novartis)

Alimera Sciences

Allergan

Allegro Ophthalmics

Altheos

Amakem

Ampio Pharma

Asahi Glass

AstraZeneca

Aton Pharma (acquired by Valeant)

Banyu Pharmaceutical (part of Merck)

Bausch and Lomb (subsidiary of Valeant)

Bayer

Bayer Yakuhin (Japanese subsidiary of Bayer)

BioDiem

Bicycle Therapeutics

Biogen Idec

BioInvent International

Biovail Corporation (part of Valeant)

Bristol-Myers Squibb

Can-Fite BioPharma

Chengdu Kanghong Pharmaceutical

Chiron Corportation (part of Novartis)

Chugai Pharmaceutical (part of Roche)

CIBA VISION (part of Novartis)

Ciba-Geigy (part of Novartis)

Colby Pharmaceutical Company (Colby)

CoMentis

Daiichi Sankyo

Eleven Biotherapeutics

Eli Lilly and Company (Lilly)

EyeGate Pharmaceuticals

Eyetech Inc. / Eyetech Pharmaceuticals (acquired by Valeant)

Fougera Pharmaceuticals (acquired by Novartis)

Gene Signal

Genentech (subsidiary of Roche)

Genzyme (subsidiary of Sanofi)

Gilead Sciences

GSK

ICN Pharmaceuticals (original Valeant company)

Icon Bioscience

Inamed Corporation (subsidiary of Allergan)

Inception Sciences, Inc.

InSite Vision

Inspire Pharmaceuticals (acquired by Merck)

ISTA Pharmaceuticals (part of Valeant)

Jerini AG

Jerini Ophthalmic (part of Jerini AG)

Johnson & Johnson

Kestrel Ophthalmics

Kyorin Pharmaceutical

Kyowa Hakko Kirin

LEO Pharma

Lpath

MacuCLEAR

MacuSIGHT, Inc.

MAP Pharmaceuticals (acquired by Allergan)

Meda

Medicis Corporation (acquired by Valeant)

Merck & Co. (Merck)

MerLion Pharmaceuticals

MSD K.K. (part of Merck)

Mylan Pharmaceuticals

Mystic Pharmaceuticals

Neurotech

NicOx

Nippon Boehringer Ingelheim (subsidiary of Boehringer Ingelheim)

NovaBay Pharmaceuticals

Novagali Pharma (acquired by Santen)

Novartis

Novo (subsidiary of Novo Nordisk)

Novo Nordisk

Oakwood Laboratories

OcuSciences

Omeros

Onyx Pharmaceuticals

OphthaliX (part-owned by Can-Fite BioPharma)

Ophthotech

OPKO Health

Ora

OSI Pharmaceuticals

Othera Pharmaceuticals (acquired by Colby)

Otsuka Pharmaceutical

Oxford BioMedica

OXiGENE

Parke-Davis (subsidiary of Pfizer)

PDL BioPharma

Pfizer

Pharmacia (acquired by Pfizer)

Potentia Pharmaceuticals

Premacure

Procter & Gamble

pSivida

Quark Pharmaceuticals

Reckitt Benckiser

Regeneron

RetroSense Therapeutics

ReVision Therapeutics

Roche

RXi Pharmaceuticals

Sandoz (part of Novartis)

Sanofi

Santen Pharmaceutical Co. (Santen)

SARcode Bioscience

Schering-Plough (part of Merck)

Senju

Senju Pharmaceuticals Science & Technology (Beijing) Co., Ltd. (subsidiary of Senju)

Senju USA Inc. (subsidiary of Senju)

Shire

Sirion Therapeutics

Sirna Therapeutics

Sirnaomics

SkinMedica (subsidiary of Allergan)

Spark Therapeutics

Symphony ViDA

Takeda Pharmaceutical

Teva

The Patent Board

ThromboGenics

Upjohn (acquired by Pfizer through Pharmacia)

Valeant Pharmaceuticals

Ventana Medical Systems (acquired by Roche)

Versant Ventures

Warburg Pincus LLC

Warner-Lambert (acquired by Pfizer)

Watson Pharmaceuticals

Wyeth Pharmaceuticals (part of Pfizer)

List of Other Organizations Mentioned in the Report

A*STAR Institute for Infocomm Research (Singapore)

American Academy of Ophthalmology (AAO)

American Diabetes Association

American Society of Retina Specialists (ASRS)

Association for Research in Vision and Ophthalmology (ARVO)

Council of Europe

Emory University

European Medicines Agency (EMA)

Foundation Fighting Blindness (FFB) (US)

Health Canada

Institute of Experimental Medicine (Russia)

Institute of Ocular Pharmacology, Texas A&M (US)

Institute of Ophthalmology, University College London (UK)

Intellectual Property Appellate Board (India)

International Diabetes Federation

Internet Archive

Japan Patent Office (JPO)

Mayo Clinic

Ministry of Health, Labour and Welfare (MHLW) (Japan)

Monash University

National Eye Institute (NEI) (US)

National Health Service (NHS) (UK)

National Institute for Health and Care Excellence (NICE) (UK)

NHS Scotland

Novartis Institutes for BioMedical Research (NIBR) (part of Novartis)

Novartis Venture Funds (NVF) (part of Novartis)

Ophthalmology External Research Unit (part of Pfizer)

Ophthrisi (GSK research unit)

Rinat (Pfizer research unit)

Texas Emerging Technology Fund

Therapeutic Goods Administration (TGA) (Australia)

Tokyo University of Science

United States Food and Drug Administration (FDA)

University of Florida

University of Kentucky

University of Melbourne

University of Michigan

US Preventive Services Task Force (USPSTF)

US Securities and Exchange Commission (SEC)

World Health Organization (WHO)

Download sample pages

Complete the form below to download your free sample pages for Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2018-2028

Download sample pages

Complete the form below to download your free sample pages for Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2018-2028

Case studies

Need customized work?

Report overview

Methodology

Client testimonials

Pharmaceutical industry associations

American Association of Colleges of Pharmacy
American College of Clinical Pharmacy
American Pharmacists Association
American Society for Pharmacy Law
American Society of Consultant Pharmacists
American Society of Health-System Pharmacists
Association of Special Pharmaceutical Manufacturers
Australian College of Pharmacy
Biotechnology Industry Organization
Canadian Pharmacists Association
Canadian Society of Hospital Pharmacists
Chinese Pharmaceutical Association
College of Psychiatric and Neurologic Pharmacists
Danish Association of Pharmaconomists
European Association of Employed Community Pharmacists in Europe
European Medicines Agency
Federal Drugs Agency
General Medical Council
Head of Medicines Agency
International Federation of Pharmaceutical Manufacturers & Associations
International Pharmaceutical Federation
International Pharmaceutical Students’ Federation
Medicines and Healthcare Products Regulatory Agency
National Pharmacy Association
Norwegian Pharmacy Association
Ontario Pharmacists Association
Pakistan Pharmacists Association
Pharmaceutical Association of Mauritius
Pharmaceutical Group of the European Union
Pharmaceutical Society of Australia
Pharmaceutical Society of Ireland
Pharmaceutical Society Of New Zealand
Pharmaceutical Society of Northern Ireland
Professional Compounding Centers of America
Royal Pharmaceutical Society
The American Association of Pharmaceutical Scientists
The BioIndustry Association
The Controlled Release Society
The European Federation of Pharmaceutical Industries and Associations
The European Personalised Medicine Association
The Institute of Clinical Research
The International Society for Pharmaceutical Engineering
The Pharmaceutical Association of Israel
The Pharmaceutical Research and Manufacturers of America
The Pharmacy Guild of Australia
The Society of Hospital Pharmacists of Australia

Connect with us

Visiongain Pharma

Latest Pharma news

Visiongain Publishes Allergy Immunotherapy Market Report 2023-2033

The global Allergy Immunotherapy market is projected to grow at a CAGR of 7.6% by 2033

31 May 2023

READ

Visiongain Publishes AI-based Clinical Trial Solution Providers Market Report 2023-2033

The global AI-based Clinical Trial Solution Providers market was valued at US$1,232.0 million in 2022 and is projected to grow at a CAGR of 23.3% during the forecast period 2023-2033.

26 May 2023

READ

Visiongain Publishes Vaccine Contract Manufacturing Market Report 2023-2033

The global Vaccine Contract Manufacturing Market is projected to grow at a CAGR of 13.2% by 2033

24 May 2023

READ

Visiongain Publishes Cell & Gene Therapy Cold Chain Logistics Market Report 2023-2033

The global Cell & Gene Therapy Cold Chain Logistics market is projected to grow at a CAGR of 15% by 2033

23 May 2023

READ

Industries > Pharma > Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2018-2028

Back to Pharma Reports

Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2018-2028

Retinal Disorder Drugs, Allergic, Inflammatory & Infective Drugs, Glaucoma Drugs, Dry Eye Drugs

Download sample pages

Related reports

Global Ophthalmic Drugs Market Forecast 2018-2028

Global Pre-Filled Syringes Market Forecast 2017-2027

Top 25 Antibiotic Drugs Manufacturers 2018

Global Ophthalmic Drugs Market Forecast 2019-2029

Global Infusion Devices Market Forecast 2018-2028

Global Ophthalmic Devices Market 2018-2028

Generic Drugs Market Forecast 2018-2028

Dermatological Drugs Market Forecast 2018-2028

Medical Devices Leader Series: Top In Vitro Diagnostics (IVD) Companies 2017-2027

The Ophthalmic Equipment Market Forecast 2019-2029

Download sample pages

Share

Connect with us

Latest Pharma news

Visiongain Publishes Allergy Immunotherapy Market Report 2023-2033

Visiongain Publishes AI-based Clinical Trial Solution Providers Market Report 2023-2033

Visiongain Publishes Vaccine Contract Manufacturing Market Report 2023-2033

Visiongain Publishes Cell & Gene Therapy Cold Chain Logistics Market Report 2023-2033

Our Clients